LifeStance Health Group, Inc.
LFSTHealthcareNASDAQMedical Care Facilities · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, LifeStance Health Group, Inc. focuses on Medical Care Facilities services and products. LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. Valued at $4.92B, LFST is a mid-cap name in its sector. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.
Market Cap
$4.92B
Beta
1.24
P/E (TTM)
99.46
P/E (Fwd)
30.02
EPS (TTM)
$0.13
EPS (Fwd)
$0.43
ROE
3.4%
ROA
2.3%
Cash
$225.9M
Total Debt
$474.2M
Free CF
$172.4M
52W Change
148.7%
Annual Financials
Cash vs Debt
Where LFST stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, LFST finished 20.72% above its 150-day moving average ($9.75) and 29.63% above its 200-day moving average ($9.08). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LFST overbought or oversold?
At the October 20, 2026 close, LFST's RSI(14) was 47.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
LifeStance Health Group, Inc. carries $474.2M in total debt against $225.9M in cash reserves — debt is roughly 2.1x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $172.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 3.4% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.3% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $859.5M (2022) to $1.42B (2025), reflecting a 66% increase over the period.
The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence LifeStance Health Group, Inc.'s trajectory.